| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 19th November 2020 | Kathryn E Falberg | 795 | Open or private sale | $807.84 | $642,232.80 |
| 19th November 2020 | Kathryn E Falberg | 20,000 | Conversion of derivative | $0.00 | |
| 19th November 2020 | Kathryn E Falberg | 891 | Open or private sale | $813.04 | $724,418.64 |
| 19th November 2020 | Kathryn E Falberg | 232 | Open or private sale | $806.63 | $187,138.16 |
| 19th November 2020 | Kathryn E Falberg | 1,853 | Open or private sale | $809.03 | $1,499,132.59 |
| 19th November 2020 | Kathryn E Falberg | 5,670 | Open or private sale | $811.00 | $4,598,370.00 |
| 19th November 2020 | Kathryn E Falberg | 1,891 | Open or private sale | $815.00 | $1,541,165.00 |
| 19th November 2020 | Kathryn E Falberg | 10 | Open or private sale | $814.00 | $8,140.00 |
| 19th November 2020 | Kathryn E Falberg | 200 | Open or private sale | $811.68 | $162,336.00 |
| 19th November 2020 | Kathryn E Falberg | 2,852 | Open or private sale | $810.19 | $2,310,661.88 |
Arcus Biosciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Ticker: RCUS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1724521
Employees: 139
Exchange: New York Stock Exchange
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $285 M (0%)
Assets, Current: $472 M (144%)
Property, Plant and Equipment, Net: $8 M (-11%)
Other Assets, Noncurrent: $1 M (51%)
Assets: $481 M (137%)
Accounts Payable, Current: $12 M (156%)
Accrued Liabilities, Current: $6 M (0%)
Liabilities, Current: $40 M (76%)
Other Liabilities, Noncurrent: $693 Th (-14%)
Liabilities: $53 M (34%)
Common Stock, Value, Issued: $6 Th (50%)
Common Stock, Shares, Issued: $59 M (28%)
Retained Earnings (Accumulated Deficit): $278 M (35%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $144 Th (125%)
Stockholders' Equity (Parent): $429 M (0%)
Liabilities and Equity: $481 M (137%)
Revenue: $2 M (-50%)
Research and Development: $36 M (-39%)
General and Administrative Expenses: $11 M (-38%)
Operating Income/Loss: $45 M (-38%)
Other Income, net: $301 Th (-68%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
